03.02.2024 - SAN CARLOS, Calif., Feb. 02, 2024 (GLOBE NEWSWIRE) - Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the .
16.10.2023 - - New Agreement to Establish Global Commercial Manufacturing Capacity for Vaxcyte s PCV Candidates, VAX-24 and VAX-31, in Adult and Pediatric Populations - - Expanded Collaboration Builds on Vaxcyte’s Current Strategy to Conduct Initial Commercial . Seite 1